Introduction: Managing agitation in the clinical setting is a challenge that many practitioners face regularly. Our evolving understanding of the etiological factors involved in aggressive acts has better informed our interventions through pharmacologic and behavioral strategies. This paper reviews the literature on the neurobiological underpinnings of aggressive behaviors, linking psychopathology with proposed mechanisms of action of psychiatric medications shown to be effective in mitigating agitation.

Methods: We performed a review of the extant literature using PubMed as a primary database. Investigation focused on neurobiology of agitation and its relation to the current evidence base for particular interventions.

Results: There are well-established pathways that can lead to increased autonomic response and the potential for violence. Psychopathology and substance-induced perceptual distortions may lead to magnification and overestimation of environmental threat, heightening the potential for aggression. Additional challenges have arisen with the advent of several novel drugs of abuse, many of which lead to atypical clinical presentations and which can elude standard drug screens. Our interventions still lean on the evidence base found in Project BETA (Best Practices in Evaluation and Treatment of Agitation). Although not a new drug and not included in the Project BETA guidelines, ketamine and its use are also discussed, given its unique pharmacology and potential benefits when other protocoled interventions have failed.

Conclusion: Aggression can occur due to manifold reasons in the clinical setting. Having an informed understanding of the possible determinants of agitation can help with more tailored responses to individual patients, limiting the unnecessary use of medications or of interventions that could be deemed forceful.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390566PMC
http://dx.doi.org/10.5811/westjem.2020.4.45779DOI Listing

Publication Analysis

Top Keywords

neurobiology agitation
8
clinical setting
8
evidence base
8
project beta
8
agitation
5
current understanding
4
understanding neurobiology
4
agitation introduction
4
introduction managing
4
managing agitation
4

Similar Publications

Hyperphosphorylated tau accumulation is seen in the noradrenergic locus coeruleus from the earliest stages of Alzheimer's disease onwards and has been associated with symptoms of agitation. It is hypothesized that compensatory locus coeruleus-noradrenaline system overactivity and impaired emotion regulation could underlie agitation propensity, but to our knowledge this has not previously been investigated. A better understanding of the neurobiological underpinnings of agitation would help the development of targeted prevention and treatment strategies.

View Article and Find Full Text PDF

There have been important updates in the guidelines for the management of agitation in emergency room settings, including psychiatric emergency services. This manuscript provides a synthesis of current recommendations, combined with a detailed breakdown of the neurobiology of agitation, linking these neuroscientific dimensions with the pharmacological profiles of the drugs recommended by practice guidelines (as well as the profiles of other important agents). Since Project BETA (Best Practices in Evaluation and Treatment of Agitation) guidelines were published in 2012 (by the American Association for Emergency Psychiatry), there have been several developments in the standard of care, including an increase in use of ketamine and droperidol.

View Article and Find Full Text PDF

Behavioral disorders in Parkinson disease: current view.

J Neural Transm (Vienna)

October 2024

Institute of Clinical Neurobiology, Alberichgasse 5/13, 1150, Vienna, Austria.

Patients with Parkinson disease (PD) frequently experience several behavioral symptoms, such as anxiety, apathy, irritability, agitation, impulsive control and obsessive-compulsive or REM sleep behavior disorders, which can cause severe psychosocial problems and impair quality of life. Occurring in 30-70% of PD patients, these symptoms can manifest at early stages of the disease, sometimes even before the appearance of classic motor symptoms, while others can develop later. Behavioral changes in PD show distinct patterns of brain atrophy, dopaminergic and serotonergic deterioration, altered neuronal connectivity in frontostriatal, corticolimbic, default mode and other networks due to a cascade linking molecular pathologies and deficits in multiple behavior domains.

View Article and Find Full Text PDF

Behavioral disorders in dementia with Lewy bodies: old and new knowledge.

J Neural Transm (Vienna)

September 2024

Institute of Clinical Neurobiology, Alberichgasse 5/13, Vienna, A-1150, Austria.

Dementia with Lewy bodies (DLB), the second most common primary degenerative neurocognitive disorder after Alzheimer disease, is frequently preceded by REM sleep behavior disorders (RBD) and other behavioral symptoms, like anxiety, irritability, agitation or apathy, as well as visual hallucinations and delusions, most of which occurring in 40-60% of DLB patients. Other frequent behavioral symptoms like attention deficits contribute to cognitive impairment, while attention-deficit/hyperactivity disorder (ADHD) is a risk factor for DLB. Behavioral problems in DLB are more frequent, more severe and appear earlier than in other neurodegenerative diseases and, together with other neuropsychiatric symptoms, contribute to impairment of quality of life of the patients, but their pathophysiology is poorly understood.

View Article and Find Full Text PDF

Behavioral disorders in multiple sclerosis: a comprehensive review.

J Neural Transm (Vienna)

January 2025

Institute of Clinical Neurobiology, Alberichgasse 5/13, Vienna, A-1150, Austria.

Article Synopsis
  • Multiple sclerosis (MS) is a complex autoimmune disease affecting the central nervous system, leading to symptoms such as inflammation, demyelination, and cognitive impairment, with behavioral changes often emerging early and escalating with disease progression.
  • About 30 to 80% of MS patients experience behavioral disorders such as anxiety, aggression, and executive dysfunction, which can combine with depression but are generally not linked to motor skill declines.
  • Neuroimaging studies indicate that MS is associated with specific brain changes and that therapeutic interventions like psychology, behavior modification, and exercise show promise in managing these symptoms and improving patients' quality of life.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!